一例局部晚期乳腺癌的循证综合治疗讨论
摘要
为了给晚期转移性乳腺癌患者带来更多的临床获益,使其拥有更高生活质量的同时能够获得长期生存的机会,我们就一个乳腺癌患者的检查和治疗等方面进行了讨论。
出处
《海南医学》
CAS
2012年第1期135-137,共3页
Hainan Medical Journal
参考文献11
-
1Robert NJ,Eierrnann W,Pienkowski T,et al.BCIRG 006:Docetax.el and trastuzumab-based regimens improve DFS and OS over AC followed by T in node positive and high risk node negative HER2 positive early breast cancer patients:Quality of life at 36 months follow-up[J].J Clin Oncol,2007,25(18S):19647.
-
2Joensuu H,Kellokumpu-Lentinen P-L,Bono P,et al.Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer[J].N Engl J Med,2006,354:809-820.
-
3Martin M,Pienkowski T,Mackey J,et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med,2005,352(22):2302-2313.
-
4Dang C,Fomier M,Sugaman S,et al.The safety of dose-dense doxorubicin and cyclophosphamide followed by paditaxel with trastuzumab in HER2/neu overexpressed/amplified breast cancer[J].J Clin Oncol,2008,26:1216-1222.
-
5Seidman AD.Gemcitabine as single-agent therapy in the management of advanced breast cancer[J].Oncology(Huntingt),2001,15(Suppl 3):11-14.
-
6Romond EH,Perez EZ,Bryant J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer[J].N Engl J Med,2005,353:1673-1684.
-
7O' Shaughnessy J,Miles D,Vukelja S,et al.Superior survival with capecitabine plus paclitaxel(GT)vs.paclitaxel(T)as frontline therapy for metastatic breast cance(MBC); First Report of Overall Survival[J].J Clin Oncol,2004,22(14S):510.
-
8Bull JM,Tormey DC,Li SH,et al.A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy[J].Cancer,1978,41:1649-1657.
-
9Hillner BE,Lngle JN,Chlebowski RT,et al.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women the breast cancer[J].J Clin Oncol,2003,21(21):4042-4057.
-
10Gralow JR,Biermann JS,Farooki A,et al.NCCN Task Force Report:Bone health in cancer care[J].J Natl Compr Canc Netw,2009,7(S3):1-32.
二级参考文献12
-
1王涛,江泽飞,宋三泰,张少华,申戈,于静新.单药希罗达治疗复发转移性乳腺癌的疗效观察[J].中华肿瘤杂志,2004,26(6):379-381. 被引量:57
-
2Rivera E,Valero V,Arun B,et al.Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.J Clin Oncol,2003,21(17):3249-3254.
-
3Blackstein M,Vogel CL,Ambinder R,et al.Gemcitabine as first-line therapy in patients with metastatic breast cancer:a phase Ⅱ trial.Oncology,2002,62(1):2-8.
-
4Seidman AD.Gemcitabine as single-agent therapy in the management of advanced breast cancer.Oncology (Williston Park),2001,15(2 Suppl 3):11-14.
-
5dRuíz GC,Fuentes de la Pe鼻a H,Meza FA,et al.A phase Ⅱ study of gemcitabine plus cisplatin in metastatic breast cancer (MBC).Proc Am SocClin Oncol,2001,20:60b.
-
6Malmstr(O)m A,Hansen J,Malmberg L,et al.Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treatedbreast cancer patients:A phase Ⅱ study.Acta Oncol,2010,49(1):35-41.
-
7Ciruelos EM,Cortés J,Cortés-Funes H,et al.Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer:amulticenter phase Ⅱ study (SOLTI 0301 trial).Ann Oncol,2010,21(7):1442-1447.
-
8Pérez-Manga G,López-Criado P,Mendez M,et al.Gemcitabine (G) plus capecitabine (C) in previously treated metastatic breast cancer (MBC)patients.Results from a phase Ⅱ GOTI trial.Breast Cancer Res Treat,2004,88(Suppl 1):5063 (Abstract).
-
9Sikov WM,Theall KP,Seidler R,et al.Gemcitabine and capecitabine in metastatic breast cancer (MBC):Brown University Oncology group (BrUOG) phaseⅡstudy.J Clin Oncol,2005,23:785.
-
10Ahn J,K im S,Lee Y,et al.Phase Ⅱ study of gemcitabine and capecitabine in patients with metastatic breast cancer pretreated withanthracyclinesandtaxanes.J Clin Oncol,2005,23:895.
共引文献24
-
1李玺,姜华,郭卫平,邱万寿,黄勇,吴珏堃,刘瑞磊,黄泽楠,刘仁斌.卡培他滨引起的手足综合征发病特点与治疗观察[J].中华临床医师杂志(电子版),2011,5(6):1781-1783. 被引量:19
-
2陆海林,李燕,宁志强,曹婷华,陈超.多西他赛联合卡培他滨治疗复发转移乳腺癌的疗效及相关因素研究[J].临床肿瘤学杂志,2011,16(10):905-908. 被引量:22
-
3刘桂兰,冯艳红,侯慧科,刘京,张毛讲.吉西他滨联合卡培他滨治疗蒽环类耐药的转移性乳腺癌的临床疗效和安全性分析[J].肿瘤药学,2013,3(5):357-360. 被引量:18
-
4郭千弘,马建瓴,张炯,王秦西.卡培他滨与5-氟尿嘧啶引起手足综合征的临床观察[J].中国医药指南,2013,11(31):36-37. 被引量:8
-
5代翠莲,张先舵,李淑萍.替吉奥与希罗达分别联合多西他赛治疗转移性乳腺癌的对照研究[J].中国医疗前沿,2013,8(19):64-64. 被引量:2
-
6周勇,彭世军.复发转移乳腺癌药物治疗基本原则和新策略[J].检验医学与临床,2014,11(2):255-256. 被引量:4
-
7蒋祥德,刘友如,施朕善.吉西他滨联合卡培他滨治疗复发转移性乳腺癌的临床观察[J].安徽医药,2014,18(2):335-336. 被引量:6
-
8吴超.复发转移性乳腺癌癌胚抗原及糖类抗原水平与卡培他滨疗效和预后的关系研究[J].中国药业,2015,24(6):15-16. 被引量:4
-
9朱婷婷.吉西他滨联合卡培他滨方案治疗晚期乳腺癌的效果[J].当代医学,2015,21(11):143-144. 被引量:2
-
10房慧,苏丹,张婷婷,张勇,夏学名,白莉.卡培他滨单药维持治疗晚期胃癌疗效分析[J].解放军医学院学报,2015,36(7):675-678. 被引量:7
-
1陈玲.“循证”肺癌治疗[J].中国处方药,2003(4):77-77.
-
2张应天.循证乳癌外科[J].临床外科杂志,2000,8(5):257-258. 被引量:5
-
3杨甲梅.大肝癌治疗方法的循证选择[J].中华医学信息导报,2011,26(12):12-12. 被引量:3
-
4刘长青.骨转移的检查和治疗[J].癌症康复,2000(2):22-22.
-
5陈宙,金乃时.内镜检查和治疗消化道息肉101例分析[J].安徽医科大学学报,1990,25(4):299-301.
-
6吴平利.多西紫杉醇联合顺铂和5-氟尿嘧啶治疗晚期胃癌的疗效观察[J].中国医药科学,2012,2(15):60-61. 被引量:3
-
7李立.survivin、Ki-67在口腔癌中的表达及预后意义[J].陕西医学杂志,2009,38(2):159-161. 被引量:2
-
8无,高惠冰,郑登云.局部晚期喉癌的多学科治疗[J].循证医学,2016,16(5):317-320. 被引量:1
-
9沈士芳.拥有健康[J].癌症康复,2000(2):24-25.
-
10雷云菲.食管癌术后胃排空障碍40例循证护理分析[J].中国现代药物应用,2014,8(16):183-183.